Get the Stockscreener App
0.62
6.81%
-0.0453
Celularity Inc stock is traded at $0.62, with a volume of 222.08K.
It is down -6.81% in the last 24 hours and down -30.87% over the past month.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
See More
Previous Close:
$0.6653
Open:
$0.64
24h Volume:
222.08K
Relative Volume:
1.91
Market Cap:
$17.95M
Revenue:
$26.55M
Net Income/Loss:
$-91.72M
P/E Ratio:
-0.173
EPS:
-3.584
Net Cash Flow:
$-13.25M
1W Performance:
-17.59%
1M Performance:
-30.87%
6M Performance:
-53.73%
1Y Performance:
-67.54%
1-Day Range:
$0.566
$0.68
1-Week Range:
$0.566
$0.7599
52-Week Range:
$0.566
$4.35
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
0.62 | 17.95M | 26.55M | -91.72M | -13.25M | -3.584 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Enterprise value to EBITDA forward of Celularity Inc. – NASDAQ:CELU - TradingView
Price to sales forward of Celularity Inc. – NASDAQ:CELU - TradingView
Celularity Inc (CELU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Celularity appoints Steven N. Gordon as COO and K. Harold Fletcher as CLO & Corporate Secretary - TradingView
New leadership at Celularity (NASDAQ: CELU) as Gordon joins board - Stock Titan
Celularity Inc. Class A Actuals & Estimates (NASDAQ:CELU) - TradingView
Form 4 Celularity Inc For: 23 June By Investing.com - Investing.com South Africa
Barach Family Trust (CELU) lets $2M note, warrant options lapse while holding large derivatives - Stock Titan
Celularity (NASDAQ: CELU) insider trust sees $2M note option expire - Stock Titan
Celularity (NASDAQ: CELU) major holder’s $2M note option and 839K warrants expire - Stock Titan
Form 13D/A Celularity Inc. For: 23 June By Investing.com - Investing.com Australia
Barach Family Trust updates 15.8% Celularity (CELU) stake in 13D/A - Stock Titan
CELU Technical Analysis & Stock Price Forecast - Intellectia AI
Penny Stocks: Why Is Celularity (CELU) Stock Trending Today? - TipRanks
Celularity Inc (CELU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Celularity Inc (CELU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Celularity Inc (CELU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Celularity Inc (CELU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Celularity Inc (CELUW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Celularity Inc (CELUW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Celularity Inc (CELUW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Celularity Inc (CELUW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Celularity Inc (CELUW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Celularity Inc (CELUW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Celularity Inc (CELUW) Institutional Confidence - TradingKey
Celularity Inc (CELUW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Celularity Inc (CELU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celularity Inc (CELU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Celularity Inc (CELU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Celularity Inc (CELU) Institutional Confidence - TradingKey
Celularity Inc (CELUW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celularity Inc. Warrant (CELUW) Holds at $0.01 Amid Minimal Volatility – Key Levels in FocusPCR Moving Average - newsline.com
Celularity Faces Nasdaq Listing Compliance Risk After Notice - The Globe and Mail
Celularity Inc. 8-K Filing June 2026: Nasdaq Listing, Company Details, and Securities Information - Minichart
Celularity receives Nasdaq notice for non-compliance with $35 million market value rule - Investing.com
Celularity Received Notice of Noncompliance - TradingView
[8-K] Celularity Inc Reports Material Event - Stock Titan
Celularity (CELU) Slips 6% as Stock Approaches Key Support at $0.69Price Gap Fill - newsline.com
Celularity Inc. (CELU) Slips 7.4% as Selling Pressure Continues Near Key SupportLow Volatility Picks - newsline.com
CELU - Finviz
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies - The Manila Times
New Florida law lets doctors use placental cell therapy before FDA approval - Stock Titan
Celularity names Rick Gonzalez as chief commercial officer - Investing.com UK
Celularity: Actions Are Intended to Streamline Business and Concentrate Resources >CELU - Moomoo
Celularity refocuses on cell therapy after biomaterials sale - Investing.com
Celularity Appoints Rick Gonzalez as Chief Commercial Officer - TipRanks
Celularity names Rick Gonzalez as Chief Commercial Officer - TradingView
New Celularity (NASDAQ: CELU) CCO to drive cenplacel-L and Lifebank growth - Stock Titan
Celularity refocuses on cell therapy after biomaterials sale By Investing.com - Investing.com UK
Celularity Releases CEO Letter to Shareholders - The Manila Times
Celularity outlines placenta cell therapy push to extend health span - Stock Titan
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):